18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance on June 28, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each...
05:15 , Jun 28, 2018 |  BC Extra  |  Financial News

Tricida gains, others dip after upsized IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance Thursday, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each lost ground....
13:47 , Jun 5, 2018 |  BC Extra  |  Financial News

Tricida files for $150M IPO

Renal disease company Tricida Inc. (South San Francisco, Calif.) filed to raise up to $150 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan and Cowen. In 2H19, Tricida plans to submit...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Kiklin bixalomer regulatory update

Astellas said Japan approved an sNDA for a granule formulation of Kiklin bixalomer to treat hyperphosphatemia in patients on dialysis with chronic kidney disease (CKD). In 2012, Astellas launched a capsule formulation of the metal-free,...
07:00 , Aug 1, 2016 |  BioCentury  |  Finance

Tricida: Ilypsa 3.0?

Although both Tricida Inc. and one of its investors are keeping tight-lipped about the biotech's technology and development plans, it appears both are hoping Tricida is the next version of Relypsa Inc. (NASDAQ:RLYP) and its...
07:00 , May 30, 2016 |  BioCentury  |  Finance

It takes a village

5AM Ventures isn't about to jump on the bandwagon with other early stage biotech venture firms that are raising large funds with the goal of forming smaller syndicates and retaining larger ownership stakes. Instead, the...
07:00 , Apr 18, 2016 |  BioCentury  |  Finance

Double-dipping

If takeout rumors about Relypsa Inc. (NASDAQ:RLYP) come true, 5AM Ventures is well positioned to improve upon the returns it has already achieved on the second of two lucrative sibling investments in chronic kidney disease...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Kiklin bixalomer regulatory update

Astellas said Japan approved an sNDA for Kiklin bixalomer capsules to include treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) who are not on dialysis. Previously, Kiklin was indicated only in CKD patients...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Kiklin bixalomer regulatory update

Astellas submitted an sNDA to Japan for a granule formulation of Kiklin bixalomer to treat hyperphosphatemia in patients on dialysis with chronic kidney disease (CKD). In 2012, Astellas launched a capsule formulation of the metal-free,...
07:00 , Oct 15, 2012 |  BioCentury  |  Product Development

Gut instinct

Ardelyx Inc. took its gut-specific small molecule approach from concept to Phase II testing in under four years and now has scored a partnership with AstraZeneca plc as the pharma adds diabetic complications as a...